The Experts below are selected from a list of 465 Experts worldwide ranked by ideXlab platform
Catherine Parker - One of the best experts on this subject based on the ideXlab platform.
-
the incidence of adjacent synchronous invasive carcinoma and or ductal carcinoma in situ in patients with Intraductal Papilloma without atypia on core biopsy results from a prospective multi institutional registry tbcrc 034
Annals of Surgical Oncology, 2021Co-Authors: Faina Nakhlis, Gabrielle M Baker, Melissa Pilewskie, Rebecca Gelman, Katherina Zabicki Calvillo, Kandice K Ludwig, Priscilla F Mcauliffe, Shawna C Willey, Laura H Rosenberger, Catherine ParkerAbstract:Available retrospective data suggest the upgrade rate for Intraductal Papilloma (IP) without atypia on core biopsy (CB) ranges from 0 to 12%, leading to variation in recommendations. We conducted a prospective multi-institutional trial (TBCRC 034) to determine the upgrade rate to invasive cancer (IC) or ductal carcinoma in situ (DCIS) at excision for asymptomatic IP without atypia on CB. Prospectively identified patients with a CB diagnosis of IP who had consented to excision were included. Discordant cases, including BI-RADS > 4, and those with additional lesions requiring excision were excluded. The primary endpoint was upgrade to IC or DCIS by local pathology review with a predefined rule that an upgrade rate of ≤ 3% would not warrant routine excision. Sample size and confidence intervals were based on exact binomial calculations. Secondary endpoints included diagnostic concordance for IP between local and central pathology review and upgrade rates by central pathology review. The trial included116 patients (median age 56 years, range 24–82) and the most common imaging abnormality was a mass (n = 91, 78%). Per local review, 2 (1.7%) cases were upgraded to DCIS. In both of these cases central pathology review did not confirm DCIS on excision. Additionally, central pathology review confirmed IP without atypia in core biopsies of 85/116 cases (73%), and both locally upgraded cases were among them. In this prospective study of 116 IPs without atypia on CB, the upgrade rate was 1.7% by local review, suggesting that routine excision is not indicated for IP without atypia on CB with concordant imaging findings.
-
the incidence of adjacent synchronous invasive carcinoma and or ductal carcinoma in situ in patients with Intraductal Papilloma without atypia on core biopsy results from a prospective multi institutional registry tbcrc 034
Annals of Surgical Oncology, 2020Co-Authors: Faina Nakhlis, Gabrielle M Baker, Melissa Pilewskie, Rebecca Gelman, Katherina Zabicki Calvillo, Kandice K Ludwig, Priscilla F Mcauliffe, Shawna C Willey, Laura H Rosenberger, Catherine ParkerAbstract:Background Available retrospective data suggest the upgrade rate for Intraductal Papilloma (IP) without atypia on core biopsy (CB) ranges from 0 to 12%, leading to variation in recommendations. We conducted a prospective multi-institutional trial (TBCRC 034) to determine the upgrade rate to invasive cancer (IC) or ductal carcinoma in situ (DCIS) at excision for asymptomatic IP without atypia on CB. Methods Prospectively identified patients with a CB diagnosis of IP who had consented to excision were included. Discordant cases, including BI-RADS > 4, and those with additional lesions requiring excision were excluded. The primary endpoint was upgrade to IC or DCIS by local pathology review with a predefined rule that an upgrade rate of ≤ 3% would not warrant routine excision. Sample size and confidence intervals were based on exact binomial calculations. Secondary endpoints included diagnostic concordance for IP between local and central pathology review and upgrade rates by central pathology review. Results The trial included116 patients (median age 56 years, range 24-82) and the most common imaging abnormality was a mass (n = 91, 78%). Per local review, 2 (1.7%) cases were upgraded to DCIS. In both of these cases central pathology review did not confirm DCIS on excision. Additionally, central pathology review confirmed IP without atypia in core biopsies of 85/116 cases (73%), and both locally upgraded cases were among them. Conclusion In this prospective study of 116 IPs without atypia on CB, the upgrade rate was 1.7% by local review, suggesting that routine excision is not indicated for IP without atypia on CB with concordant imaging findings.
Wang Pei-yu - One of the best experts on this subject based on the ideXlab platform.
-
Promoting Effects of Milk on the Development of 7,12-dimethylbenz(a)anthracene (DMBA)-induced Mammary Tumors in Rats
Japan Society of Histochemistry and Cytochemistry, 2026Co-Authors: Katoh Ryohei, Zhou Hong, Wang Pei-yuAbstract:To assess the effect of milk on the development of 7,12-dimethylbenz(a)anthracene (DMBA)-induced mammary tumors, 48 female Sprague-Dawley rats treated with DMBA were divided into 3 groups and given 1 of 3 test solutions for 20 weeks as their drinking liquid: milk, estrone sulfate solution or tap water. The milk group showed a significantly great incidence (75%) in tumor development compared with the water group (38%) and was comparable to the estrone sulfate group (69%). Mean tumor number per rat in the milk group was significantly higher than that in the water group (p=0.009). We classified the mammary tumors into three histological types: Intraductal Papilloma, fibroadenoma, and adenocarcinoma. Although the percent of Intraductal Papilloma and fibroadenoma was almost same among the three groups, malignant tumor was found only in the milk and estrone sulfate groups. In conclusion, our results indicate that milk as well as estrone sulfate promotes the development of DMBA-induced mammary tumors in rat and could be associated with the occurrence of adenocarcinoma
Pascal Wuithier - One of the best experts on this subject based on the ideXlab platform.
-
solid papillary carcinoma with reverse polarity of the breast harbors specific morphologic immunohistochemical and molecular profile in comparison with other benign or malignant papillary lesions of the breast a comparative study of 9 additional case
Modern Pathology, 2018Co-Authors: Nadjla Alsadoun, Gaetan Macgrogan, Caroline Truntzer, Magali Lacroixtriki, Isabelle Bedgedjian, Mariehelene Koeb, Elsy El Alam, Dan Medioni, Michel Parent, Pascal WuithierAbstract:Solid papillary carcinoma with reverse polarity is a rare breast cancer of favorable prognosis that can be difficult to diagnose. We report here nine additional cases of this tumor, and we describe its morphologic, immunohistochemical and molecular profile in comparison to other types of papillary and micropapillary lesions of the breast that are Intraductal Papilloma with usual ductal hyperplasia, encapsulated papillary carcinoma, solid papillary carcinoma and invasive micropapillary carcinoma. We studied nine cases of this special papillary tumor and six of each other types mentioned above. We found that solid papillary carcinoma with reverse polarity harbor specific morphologic features as cuboid or tall cells with abundant eosinophilic cytoplasms located at the basal pole giving the impression of reverse nuclear polarity. Nuclei were sometimes grooved. Immunohistochemistry demonstrated the lack of myoepithelial cells, as in encapsulated papillary carcinoma and solid papillary carcinoma, questioning their invasive nature. Seven of nine solid papillary carcinoma with reverse polarity showed a low Ki67 proliferative index (Ki67 <5%). They showed expression of CK5/6 as in Intraductal Papilloma with usual ductal hyperplasia. They showed expression of calretinin and a low or lack of hormonal receptor (HR) expression that were not observed in other breast tumors studied. By whole-exome analysis, seven of nine solid papillary carcinomas with reverse polarity (78%) harbored a hotspot mutation in IDH2 (R172) that was totally absent in other groups. Six of nine tumors (67%) also harbored PRUNE2 mutation, including the two IDH2 wild-type cases. We also demonstrated for the first time in this breast tumor, immunostaining with a specific antibody IDH1/2 mutant R132/R172 (7/9) that can highlight IDH2 mutation. Moreover, transcriptomic analysis showed that proteoglycan pathway was significantly enriched. Our findings support the fact that solid papillary carcinoma with reverse polarity is a singular breast neoplasm that can be distinguished from other papillary breast tumors.
Faina Nakhlis - One of the best experts on this subject based on the ideXlab platform.
-
the incidence of adjacent synchronous invasive carcinoma and or ductal carcinoma in situ in patients with Intraductal Papilloma without atypia on core biopsy results from a prospective multi institutional registry tbcrc 034
Annals of Surgical Oncology, 2021Co-Authors: Faina Nakhlis, Gabrielle M Baker, Melissa Pilewskie, Rebecca Gelman, Katherina Zabicki Calvillo, Kandice K Ludwig, Priscilla F Mcauliffe, Shawna C Willey, Laura H Rosenberger, Catherine ParkerAbstract:Available retrospective data suggest the upgrade rate for Intraductal Papilloma (IP) without atypia on core biopsy (CB) ranges from 0 to 12%, leading to variation in recommendations. We conducted a prospective multi-institutional trial (TBCRC 034) to determine the upgrade rate to invasive cancer (IC) or ductal carcinoma in situ (DCIS) at excision for asymptomatic IP without atypia on CB. Prospectively identified patients with a CB diagnosis of IP who had consented to excision were included. Discordant cases, including BI-RADS > 4, and those with additional lesions requiring excision were excluded. The primary endpoint was upgrade to IC or DCIS by local pathology review with a predefined rule that an upgrade rate of ≤ 3% would not warrant routine excision. Sample size and confidence intervals were based on exact binomial calculations. Secondary endpoints included diagnostic concordance for IP between local and central pathology review and upgrade rates by central pathology review. The trial included116 patients (median age 56 years, range 24–82) and the most common imaging abnormality was a mass (n = 91, 78%). Per local review, 2 (1.7%) cases were upgraded to DCIS. In both of these cases central pathology review did not confirm DCIS on excision. Additionally, central pathology review confirmed IP without atypia in core biopsies of 85/116 cases (73%), and both locally upgraded cases were among them. In this prospective study of 116 IPs without atypia on CB, the upgrade rate was 1.7% by local review, suggesting that routine excision is not indicated for IP without atypia on CB with concordant imaging findings.
-
the incidence of adjacent synchronous invasive carcinoma and or ductal carcinoma in situ in patients with Intraductal Papilloma without atypia on core biopsy results from a prospective multi institutional registry tbcrc 034
Annals of Surgical Oncology, 2020Co-Authors: Faina Nakhlis, Gabrielle M Baker, Melissa Pilewskie, Rebecca Gelman, Katherina Zabicki Calvillo, Kandice K Ludwig, Priscilla F Mcauliffe, Shawna C Willey, Laura H Rosenberger, Catherine ParkerAbstract:Background Available retrospective data suggest the upgrade rate for Intraductal Papilloma (IP) without atypia on core biopsy (CB) ranges from 0 to 12%, leading to variation in recommendations. We conducted a prospective multi-institutional trial (TBCRC 034) to determine the upgrade rate to invasive cancer (IC) or ductal carcinoma in situ (DCIS) at excision for asymptomatic IP without atypia on CB. Methods Prospectively identified patients with a CB diagnosis of IP who had consented to excision were included. Discordant cases, including BI-RADS > 4, and those with additional lesions requiring excision were excluded. The primary endpoint was upgrade to IC or DCIS by local pathology review with a predefined rule that an upgrade rate of ≤ 3% would not warrant routine excision. Sample size and confidence intervals were based on exact binomial calculations. Secondary endpoints included diagnostic concordance for IP between local and central pathology review and upgrade rates by central pathology review. Results The trial included116 patients (median age 56 years, range 24-82) and the most common imaging abnormality was a mass (n = 91, 78%). Per local review, 2 (1.7%) cases were upgraded to DCIS. In both of these cases central pathology review did not confirm DCIS on excision. Additionally, central pathology review confirmed IP without atypia in core biopsies of 85/116 cases (73%), and both locally upgraded cases were among them. Conclusion In this prospective study of 116 IPs without atypia on CB, the upgrade rate was 1.7% by local review, suggesting that routine excision is not indicated for IP without atypia on CB with concordant imaging findings.
Katoh Ryohei - One of the best experts on this subject based on the ideXlab platform.
-
Promoting Effects of Milk on the Development of 7,12-dimethylbenz(a)anthracene (DMBA)-induced Mammary Tumors in Rats
Japan Society of Histochemistry and Cytochemistry, 2026Co-Authors: Katoh Ryohei, Zhou Hong, Wang Pei-yuAbstract:To assess the effect of milk on the development of 7,12-dimethylbenz(a)anthracene (DMBA)-induced mammary tumors, 48 female Sprague-Dawley rats treated with DMBA were divided into 3 groups and given 1 of 3 test solutions for 20 weeks as their drinking liquid: milk, estrone sulfate solution or tap water. The milk group showed a significantly great incidence (75%) in tumor development compared with the water group (38%) and was comparable to the estrone sulfate group (69%). Mean tumor number per rat in the milk group was significantly higher than that in the water group (p=0.009). We classified the mammary tumors into three histological types: Intraductal Papilloma, fibroadenoma, and adenocarcinoma. Although the percent of Intraductal Papilloma and fibroadenoma was almost same among the three groups, malignant tumor was found only in the milk and estrone sulfate groups. In conclusion, our results indicate that milk as well as estrone sulfate promotes the development of DMBA-induced mammary tumors in rat and could be associated with the occurrence of adenocarcinoma